Guideline Recommendations for Managing Restless Legs Syndrome (RLS) in Patients with Peripheral Neuropathy

Diagnosis

• Confirm true RLS by verifying all four diagnostic criteria (urge to move, worsening at rest, relief with movement, evening/night predominance) and differentiate it from nocturnal leg cramps, which have a distinct pathophysiology. 1

Iron Assessment and Repletion

• Serum ferritin and transferrin saturation should be measured in every patient with suspected RLS; iron repletion is indicated when ferritin ≤ 100 ng/mL or transferrin saturation < 20 %. 2
• Intravenous ferric carboxymaltose 1000 mg is strongly recommended as the first‑line iron therapy for RLS (American Academy of Sleep Medicine 2025, strong recommendation). [1][2]3

First‑Line Pharmacologic Therapy (True RLS Confirmed)

• Gabapentinoids (gabapentin enacarbil, gabapentin, or pregabalin) receive a strong recommendation as first‑line agents for RLS (American Academy of Sleep Medicine 2025). [1][2]

Dopamine Agonists – Not First‑Line

• Dopamine agonists (pramipexole, ropinirole, rotigotine) are not recommended as first‑line therapy because they carry a 7–10 % annual risk of augmentation (iatrogenic worsening of RLS symptoms). (American Academy of Sleep Medicine 2025, strong recommendation). [1][3]
• Prior exposure to dopaminergic agents can impair later responses to both dopaminergic and non‑dopaminergic treatments, even before clinical augmentation appears. 1

Second‑Line Options for Refractory RLS

• Extended‑release oxycodone or methadone (5–10 mg daily) are conditionally recommended for patients who cannot tolerate or do not respond to gabapentinoids (American Academy of Sleep Medicine 2025). [1][3]
• Opioid therapy for RLS shows minimal risk of augmentation, with no confirmed augmentation cases reported in major trials. 3

Management of Pure Neuropathic Pain (When RLS Is Excluded)

• First‑line agents for painful diabetic peripheral neuropathy include tricyclic antidepressants, duloxetine, pregabalin, or gabapentin; dopamine agonists should be avoided because neuropathic pain does not respond to dopaminergic therapy. (Diabetes/Metabolism Research and Reviews 2011). 4

Common Pitfalls to Avoid

• Do not initiate dopamine agonists without first confirming a true RLS diagnosis, as this exposes patients to unnecessary augmentation risk. 1
• Do not overlook iron deficiency; correcting low ferritin or transferrin saturation often resolves RLS symptoms without additional medication. 2
• Avoid medications that can exacerbate RLS, such as serotonergic antidepressants, dopamine antagonists, and centrally acting antihistamines. 2